The Medicines Company (MDCO) Now Covered by Analysts at Guggenheim
Stock analysts at Guggenheim initiated coverage on shares of The Medicines Company (NASDAQ:MDCO) in a report released on Monday, The Fly reports. The brokerage set a “buy” rating on the stock.
MDCO has been the topic of a number of other reports. Zacks Investment Research upgraded shares of The Medicines from a “hold” rating to a “buy” rating and set a $41.00 price target on the stock in a research report on Tuesday, August 8th. Citigroup Inc. dropped their price target on shares of The Medicines from $59.00 to $43.00 and set a “neutral” rating on the stock in a research report on Monday, July 17th. Chardan Capital restated a “buy” rating and set a $85.00 price target on shares of The Medicines in a research report on Wednesday, September 20th. Jefferies Group LLC restated a “buy” rating and set a $62.00 price target on shares of The Medicines in a research report on Wednesday, June 28th. Finally, Oppenheimer Holdings, Inc. set a $50.00 price target on shares of The Medicines and gave the stock a “hold” rating in a research report on Thursday, August 17th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $54.00.
Shares of The Medicines (MDCO) traded down 2.50% on Monday, reaching $33.13. 787,887 shares of the company’s stock were exchanged. The Medicines has a 1-year low of $30.80 and a 1-year high of $55.95. The company’s market capitalization is $2.38 billion. The stock’s 50-day moving average price is $35.89 and its 200-day moving average price is $40.15.
The Medicines (NASDAQ:MDCO) last released its quarterly earnings results on Wednesday, August 9th. The company reported ($5.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.29) by ($4.23). The Medicines had a negative return on equity of 137.20% and a negative net margin of 670.46%. The company had revenue of $18.74 million for the quarter, compared to the consensus estimate of $29.64 million. During the same quarter last year, the firm posted ($0.62) earnings per share. The firm’s quarterly revenue was down 65.8% compared to the same quarter last year. Analysts anticipate that The Medicines will post ($9.66) EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “The Medicines Company (MDCO) Now Covered by Analysts at Guggenheim” was originally posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of U.S. & international trademark and copyright law. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/10/23/the-medicines-company-mdco-now-covered-by-analysts-at-guggenheim.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in MDCO. Westfield Capital Management Co. LP raised its holdings in shares of The Medicines by 947.1% in the 2nd quarter. Westfield Capital Management Co. LP now owns 2,031,359 shares of the company’s stock worth $77,212,000 after purchasing an additional 1,837,359 shares in the last quarter. Iridian Asset Management LLC CT raised its holdings in shares of The Medicines by 21.7% in the 2nd quarter. Iridian Asset Management LLC CT now owns 3,677,746 shares of the company’s stock worth $139,791,000 after purchasing an additional 655,065 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of The Medicines by 24.1% in the 2nd quarter. Franklin Resources Inc. now owns 1,765,169 shares of the company’s stock worth $67,093,000 after purchasing an additional 343,160 shares in the last quarter. Vanguard Group Inc. raised its holdings in shares of The Medicines by 5.4% during the first quarter. Vanguard Group Inc. now owns 6,090,730 shares of the company’s stock valued at $297,837,000 after acquiring an additional 313,876 shares during the period. Finally, Macquarie Group Ltd. raised its holdings in shares of The Medicines by 44.4% during the second quarter. Macquarie Group Ltd. now owns 873,182 shares of the company’s stock valued at $33,190,000 after acquiring an additional 268,282 shares during the period.
About The Medicines
The Medicines Company is a global biopharmaceutical company. The Company is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It markets Angiomax (bivalirudin), Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).
Receive News & Ratings for The Medicines Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Medicines Company and related companies with MarketBeat.com's FREE daily email newsletter.